Fuster Francisco, Medina Luis, Vallansot Rolando, Granell Miquel, Bruguera Miquel
Departamento de Gastroenterología. Hospital Naval. Viña del Mar. Chile.
Gastroenterol Hepatol. 2007 Nov;30(9):525-30. doi: 10.1157/13111687.
Imatinib is currently the treatment of choice in chronic myeloid leukemia. The use of this drug is safe, although some cases of imatinib-induced toxic hepatitis have been reported. We present 2 patients treated with this drug who developed acute anicteric hepatitis months after starting treatment. We also review 20 reports of individual cases to characterize imatinib-induced hepatitis. Imatinib-induced hepatitis has a variable latency period, frequently of several months. Half of the patients develop anicteric hepatitis and the clinical course is generally benign. A distinguishing feature of this entity is a transitory increase in transaminase levels in patients diagnosed with hepatitis in the weeks after treatment withdrawal. Resumption of imatinib use provokes hepatitis recurrence, which can be avoided by simultaneous prednisone administration.
伊马替尼目前是慢性髓性白血病的首选治疗药物。尽管有报道称出现了一些伊马替尼诱发的中毒性肝炎病例，但该药物的使用是安全的。我们报告了2例接受此药物治疗的患者，他们在开始治疗数月后出现了急性无黄疸型肝炎。我们还回顾了20例个别病例报告，以描述伊马替尼诱发的肝炎。伊马替尼诱发的肝炎有不同的潜伏期，通常为数月。半数患者出现无黄疸型肝炎，临床病程一般为良性。该病症的一个显著特征是在停药后数周被诊断为肝炎的患者转氨酶水平短暂升高。重新使用伊马替尼会引发肝炎复发，同时给予泼尼松可避免这种情况。
